Study Evaluating AZD7798 for Treatment in Crohn's Disease Patients With an Ileostomy
← catalyst calendarNCT06681324 · readout in 1 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 2
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Triple · Other
Enrollment
24actual
Sites
17
Countries
Belgium, Italy, Netherlands +4
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-12-11 | actual | When the study began enrolling |
| Primary completion | 2026-08-20 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-09-03 | estimated | The whole study's end, after follow-up |
| First posted | 2024-11-08 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-01 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Crohn's Disease
Interventions
- Drug: AZD7798
- Other: Placebo
Primary outcomes
what the primary-completion date above is the date OFNumber of participants with adverse events
measured from Week 0 to Week 12
Number of participants with abnormal Vital signs: Blood pressure
measured from Week 0 to Week 12
Number of participants with abnormal Vital signs: Pulse rate
measured from Week 0 to Week 12
Number of participants with abnormal values in haematology: complete blood count (CBC)
measured from Week 0 to Week 12
Number of participants with abnormal values in haematology: white blood cell (WBC) count
measured from Week 0 to Week 12
Number of participants with abnormal values in haematology: RBC
measured from Week 0 to Week 12
Number of participants with abnormal values in clinical chemistry: kidney function
measured from Week 0 to Week 12
Number of participants with abnormal values in clinical chemistry: electrolytes
measured from Week 0 to Week 12
Number of participants with abnormal values in clinical chemistry: liver function
measured from Week 0 to Week 12
Number of participants with abnormal values in clinical chemistry: hs-CRP
measured from Week 0 to Week 12
Number of participants with abnormal values in clinical chemistry: glucose
measured from Week 0 to Week 12
Number of participants with abnormal values in ECG readings
measured from Week 0 to Week 12
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed